What is the mechanism of action of TB-500?

Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local. For metabolic and glycemic applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. The metabolic / endocrine interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What is the regulatory status of TB-500?

TB-500 regulatory status: Unapproved in the United States; WADA status banned (s0); research level preclinical + veterinary clinical (equine). Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For metabolic and glycemic use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the evidence base for TB-500?

TB-500's evidence base sits at preclinical + veterinary clinical (equine). The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The metabolic / endocrine interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What are the safety considerations for TB-500?

Generally well tolerated. Limited human safety data. Avoid in active cancer. For metabolic and glycemic use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. TB-500's ~2-3 days pharmacokinetic profile and subq/im administration route influence the side-effect profile in predictable ways.

How long until I see results from TB-500?

Acute effects from TB-500 appear within the first week for downstream physiological adaptation. metabolic and glycemic endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

How should TB-500 be stored and reconstituted?

Lyophilised TB-500 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Home/ Compounds/ TB-500

TB-500

Metabolic

Endocrine and metabolic applications of TB-500 span direct incretin-axis engagement, AMPK and mitochondrial signalling, and adiposity-driven inflammation. A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects. The ~2-3 days pharmacokinetic profile and subq/im administration shape the rate at which glycemic markers move; the typical TB-500 effect window in metabolic syndrome populations is 8-12 weeks.

Metabolic / Endocrine Applications

Metabolic SyndromeFatty Liver ResearchLiver MetabolismGastric EmptyingWeight Management

Key Takeaways

Metabolic lens: TB-500 is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers.
Mechanism: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool.
Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle.
Metabolic dose: 2-5 mg 1-2x weekly subq (loading phase); maintenance lower via subq/im.
Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.

Metabolic / Endocrine Mechanism

For metabolic-medicine applications, the relevant question is which of the four primary axes TB-500's mechanism engages: incretin-amylin, AMPK-mitochondrial, visceral-fat-cardiometabolic, or the appetite-and-satiety circuit. Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local. The subsections below address each in turn.

Insulin signalling and glycemic effect

TB-500's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.

Weight management and the appetite circuit

Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.

Visceral fat and the cardiometabolic axis

TB-500's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.

Metabolic / Endocrine Applications

Insulin Sensitivity

In the metabolic syndrome population, TB-500 for insulin sensitivity produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

GLP-1 Synergy

TB-500 for glp-1 synergy is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.

Energy Expenditure

Where TB-500 is used for energy expenditure, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.

Mitochondrial Biogenesis

In the metabolic syndrome population, TB-500 for mitochondrial biogenesis produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	2-5 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-5 mg	4–6 weeks initial cycle
Metabolic focus	SubQ	2-5 mg	1-2x weekly SubQ (loading phase); maintenance lower
Maintenance phase	SubQ	1-5 mg	Ongoing with periodic pauses

Dose timing for TB-500 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

TB-500 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.

TB-500 + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with TB-500's mechanism in metabolic / endocrine protocols.
TB-500 + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with TB-500's mechanism in metabolic / endocrine protocols.
TB-500 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with TB-500's mechanism in metabolic / endocrine protocols.
TB-500 + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with TB-500's mechanism in metabolic / endocrine protocols.

Safety & Regulatory Status

WADA: Banned (S0) FDA: Unapproved Research: Preclinical + veterinary clinical (equine)

Generally well tolerated. Limited human safety data. Avoid in active cancer.

Lens-specific safety considerations for metabolic / endocrine use of TB-500: Generally well tolerated. Limited human safety data. Avoid in active cancer. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Thymosin β4 and tissue regeneration

PMID 19737543

Supporting

Thymosin β4 — actin sequestration and repair

PMID 22515427

TB-500 vs Related Peptides

Compound	Profile	Onset	Best For
TB-500	Synthetic thymosin β4 fragment	~2-3 days	Metabolic
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding
Cagrilintide	Long-acting amylin analogue	~7 days	A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction

Frequently Asked Questions

Will I regain weight after stopping TB-500?

For most compounds in this class, partial weight regain after discontinuation is the typical pattern unless dietary and activity inputs have been fundamentally changed during the cycle. Metabolic-medicine practice increasingly frames peptide therapy as chronic rather than time-limited for weight management indications.

What metabolic labs should I track?

Baseline panel: fasting glucose, HbA1c, fasting insulin, HOMA-IR, lipid panel, ALT/AST, hsCRP, lipoprotein(a), uric acid, urinalysis. Follow-up at 6–8 weeks and 12 weeks. Add waist circumference and — ideally — DEXA or visceral-fat imaging for body-composition tracking.

Is TB-500 appropriate alongside metformin or other diabetes medications?

Most peptide compounds are compatible with metformin and complementary to sulfonylurea or insulin therapy with appropriate dose adjustment. Users on sulfonylureas or insulin should have those doses re-evaluated when adding TB-500 to avoid hypoglycaemia. Metformin combinations are generally well-tolerated and frequently used in metabolic medicine clinics.

What weight loss can I expect?

TB-500-attributable weight loss varies substantially by compound class, baseline body composition, and dietary and activity context. Direct incretin agonists produce the largest effect sizes in current literature; other peptide classes contribute more modestly and primarily through metabolic flexibility and inflammation reduction. Total trajectory matters more than first-month results.

How does TB-500 affect glycemic and metabolic markers?

TB-500's metabolic effects depend on whether it engages the incretin-amylin axis directly or operates through inflammation, mitochondrial, or adiposity pathways. Effects on glycemic markers tend to be gradual and operate through metabolic flexibility, inflammation reduction, and adiposity changes. Baseline HbA1c, fasting insulin, and — ideally — CGM during the first cycle clarify individual response.

What should I look for in TB-500 sourcing and quality?

Acceptable TB-500 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 888-1717 Da (depending on form), endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Clinical Protocol

Start a TB-500 Protocol

Alukard provides physician-supervised metabolic protocols with GMP-certified TB-500 and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get Protocol

Quick Facts

Molecular weight: 888-1717 Da (depending on form)
Sequence length: 17 aa
Half-life: ~2-3 days
WADA: Banned (S0)
FDA: Unapproved
Research: Preclinical + veterinary clinical (equine)

Stack Partners

Semaglutide (GLP-1)

Cagrilintide

MOTS-c

Tesamorelin

AOD-9604

Research Note

All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for TB-500 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised metabolic protocols

Start Your Metabolic / Endocrine Protocol for TB-500

Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised